EPSRC Centre for Doctoral Training in Tissue Engineering and Regenerative Medicine; Innovation in Medical and Biological Engineering

组织工程和再生医学博士培训中心将为75名学生提供研究生研究和培训，这些学生将能够研究、开发和提供再生疗法和设备，这些疗法和设备可以修复或替换病变组织和恢复正常组织功能。通过将新型支架与患者自己的(自体)细胞结合使用，与替代和更复杂的细胞治疗方法相比，可以以更低的成本、更短的时间和更低的风险开发出有效的组织修复无细胞再生疗法。脱细胞疗法还有一个额外的优势，因为它被监管为三级医疗设备，从而减少了开发和临床评估的成本和时间。脱细胞技术，无论是合成的还是生物的，作为商业医疗产品和NHS血液和移植作为人类移植组织的强化生物过程，都引起了工业界的极大兴趣。在这一新兴领域，越来越多的中小型公司，此外，较大的医疗技术公司看到了通过开发再生设备来扩大其医疗产品范围和解决未得到满足的临床需求的机会。英国生命科学产业战略和英国再生医学战略已经确定这是一个支持财富和健康的机会，政府最近将再生医学确定为英国的伟大技术之一。在最近的一个例子中，我们已经展示了这种新兴技术可以成功地转化为再生干预，通过用于心脏瓣膜修复和慢性伤口治疗的无细胞人体组织支架，并被商业化，正如我们的大学Spin Out Tucture Regenix所展示的那样，他们已经从动物组织中开发出无细胞支架，这已经被商业化为用于血管修复的dCEL支架。这一概念有可能应用于人体所有功能组织的修复。政府已经认识到，跨越“死亡创新谷”的创新和技术转化(下议院科学和技术特别委员会，2013年3月)具有挑战性，需要额外的创新投资。此外，我们与工业和医疗服务领域的合作伙伴发现，该领域的研究生在高水平技能和能力方面存在差距，他们接受了适当的多学科培训，以应对再生疗法和设备的应用研究、创新、评估、制造和翻译方面的挑战。这一新兴部门需要一种新型的多学科工程师，具有应用物理科学和生命科学、先进工程方法和技术方面的研究和培训，并得到创新、法规、卫生经济学和商业方面的培训，并具有再生疗法和设备领域的研究经验。CDT Term将通过将学者、行业和医疗保健专业人员聚集在一个独特的研究和创新生态系统中，为未来在新兴的再生疗法和设备领域培养和发展医疗和生物工程师，创造一个加强的多学科研究培训环境。CDT任期将由我们现有的多学科研究和创新活动和资产提供支持，其中包括超过150名多学科研究生和博士后研究人员、超过6000万GB的外部研究资金以及新的设施和实验室。我们将与我们在工业和健康服务领域的合作伙伴一起，培养和发展下一代医疗和生物工程师，他们将在英国创新和转化再生疗法和设备，推动经济增长，为健康和患者带来好处。

The Centre for Doctoral Training in Tissue Engineering and Regenerative Medicine will provide postgraduate research and training for 75 students, who will be able to research, develop and deliver regenerative therapies and devices, which can repair or replace diseased tissues and restore normal tissue function. By using novel scaffolds in conjunction with the patient`s own (autologous) cells, effective acellular regenerative therapies for tissue repair can be developed at a lower cost, reduced time and reduced risk, compared to alternative and more complex cell therapy approaches. Acellular therapies have the additional advantage as being regulated as a class three medical device, which reduces the cost and time of development and clinical evaluation. Acellular technologies, whether they be synthetic or biological, are of considerable interest to industry as commercial medical products and for NHS Blood and Transplant as enhanced bioprocesses for human transplant tissues. There are an increasing number of small to medium size companies in this emerging sector and in addition larger medical technology companies see opportunities for enhancing their medical product range and address unmet clinical needs through the development of regenerative devices. The UK Life Sciences Industry Strategy and the UK Strategy for Regenerative Medicine have identified this an opportunity to support wealth and health, and the government has recently identified Regenerative Medicine as one of UK`s Great Technologies. In one recent example, we have already demonstrated that this emergent technology be translated successfully into regenerative interventions, through acellular human tissue scaffolds for heart valve repair and chronic wound treatment, and be commercialised as demonstrated by our University spin out Tissue Regenix who have developed acellular scaffold from animal tissue, which has been commercialised as a dCEL scaffold for blood vessel repair. The concept can potentially be applied to the repair of all functional tissues in the body. The government has recognised that innovation and translation of technology across "the innovation valley of death" (Commons Science and Technology Select Committee March 2013), is challenging and needs additional investment in innovation. In addition, we have identified with our partners in industry and Health Service, a gap in high level skills and capability of postgraduates in this area, who have appropriate multidisciplinary training to address the challenges in applied research, innovation, evaluation, manufacturing, and translation of regenerative therapies and devices. This emerging sector needs a new type of multidisciplinary engineer with research and training in applied physical sciences and life sciences, advanced engineering methods and techniques, supported by training in innovation, regulation, health economics and business, and with research experience in the field of regenerative therapies and devices. CDT TERM will create an enhanced multidisciplinary research training environment, by bringing together academics, industry and healthcare professionals in a unique research and innovation eco system, to train and develop the medical and biological engineers for the future, in the emerging field of regenerative therapies and devices. The CDT TERM will be supported by our existing multidisciplinary research and innovation activities and assets, which includes over 150 multidisciplinary postgraduate and postdoctoral researchers, external research funding in excess of £60M and new facilities and laboratories. With our partners in industry and the health service we will train and develop the next generation of medical and biological engineers, who will be at the frontier in the UK in innovation and translation of regenerative therapies and devices, driving economic growth and delivering benefits to health and patients